Pharmacokinetic/Pharmacodynamic Studies for Rare Lung Diseases
Protheragen is dedicated to helping you improve the accuracy of the drug metabolism and pharmacokinetic predictions, thereby accelerating the rare lung drug discovery process and reducing development risk.
Pharmacokinetic and Pharmacodynamic Studies Critical to Developing Drugs for Rare Diseases
Pharmacokinetic (PK) and pharmacodynamic (PD) studies are important aspects of drug discovery for rare lung diseases. PK and PD studies involve targeted delivery, metabolic characterization, and efficacy assessment. These studies provide important support for drug development in rare lung diseases and also point out the direction for future research, such as optimizing drug delivery, establishing more accurate PK/PD models, and exploring new therapeutic targets.
Figure 1. Fluorescence whole-lung imaging. (Ehrmann S, et al., 2020)Our Services
How to Optimize the Dose and Efficacy of Drugs for Rare Lung Diseases by PK/PD Modeling?
We offer several services to support the optimization of dosing and efficacy of drugs for rare lung diseases:
| Our types of services | Typical examples |
|---|---|
| PK/PD modeling services | PBPK modeling for predicting free concentrations of bacteria in various lung compartments |
| PK / PD index analysis | PK/PD index analysis can be used to assess antimicrobial efficacy and typically includes parameters such as fCmax/MIC, fAUC0-24/MIC and %fT>MIC. |
| Development of new drug delivery systems | The choice of carrier material directly affects the stability, dispersion and deposition efficiency of the drug. We provide drug carrier optimization services to help you improve drug loading and bioavailability while reducing adverse reactions. |
Process of PK/PD Modeling for Rare Lung Disease Drugs
- Data collection and preliminary analysis
- Selection of appropriate modeling approaches, including empirical-based models, mechanism-based models, and hybrid modeling approaches
- Parameter estimation and model fitting
- Model validation and optimization
- Exposure-effect relationship analysis
- Individualized dose design and safety assessment
Routes of administration we support:
- Oral gavage
- Intravenous
- Subcutaneous
- Dermal
- Intra-dermal
- Intramuscular
- Intraperitoneal
Types of sample collection we support:
- Terminal blood sampling
- Terminal multiple tissue collection
- RNA sample collection
- Repetitive serum/plasma microsampling
Additional Services
Protheragen can help you predict the relationship between human exposure and effective dose in animals through animal experiments, organoid and molecular in vitro studies, and extrapolate dose/exposure-effect relationships to inform human dose design. Our PBPK model is particularly suitable for the development of drugs for rare lung diseases, as it can predict the kinetic properties of drugs in different populations by integrating physiological data.
Why Choose Us?
- Full integration of in vivo and in vitro data
- Advanced computational tools and algorithms
- Continuously optimize experimental design and model validation
- Focus on physicochemical properties of drug molecules
- Specialized strategies based on rare lung diseases
- Integration of drug interaction studies
- Adept at utilizing artificial intelligence and big data
Reference
- Ehrmann S, Schmid O, Darquenne C, et al. Innovative preclinical models for pulmonary drug delivery research. Expert Opin Drug Deliv. 2020;17(4):463-478.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.